

Applicant (Last, First, Middle): **MARIA MOLINA-MOLINA, MD, PhD**

**EDUCATION & TRAINING:**

START MONTH/YEAR	END MONTH/YEAR	DEGREE (if applicable)	INSTITUTION AND LOCATION	TRAINING MENTOR	SCIENTIFIC DISCIPLINE
<u>06/1999</u>	<u>07/2003</u>	<u>Pulmonology training</u>	<u>Hospital Clínic Barcelona</u>		<u>Pulmonology</u>
<u>07/2003</u>	<u>05/2007</u>	<u>Pre-doc</u>	<u>IDIBELL</u>	<u>Dr. A. Xaubet</u>	<u>Lung Fibrosis</u>
<u>06/2007</u>	<u>10/2008</u>	<u>Post-doc</u>	<u>IDIBELL</u>	<u>Dr. A. Xaubet</u>	<u>Lung Fibrosis</u>
<u>09/2006</u>	<u>10/2007</u>	<u>Fellowship</u>	<u>Michigan State University</u>	<u>Dr. BD. Uhal</u>	<u>Lung Fibrosis</u>

**PROFESSIONAL POSITIONS:** In reverse chronological order, list positions held since completing education and other training experiences. The last position will be your first post-training professional position entered in the Eligibility Section.

START MONTH/YEAR	END MONTH/YEAR	POSITION TITLE	DEPARTMENT	INSTITUTION AND LOCATION
<u>11/2008</u>	--	<u>Coordinator of the ILD Unit</u>	<u>Pulmonology</u>	<u>Hospital Universitario de Bellvitge</u>
<u>11/2008</u>	--	<u>Chief of the Pulmonology Research Group</u>	<u>Pulmonology</u>	<u>IDIBELL</u>
<u>08/2015</u>	--	<u>Associated Professor</u>	<u>Science Department</u>	<u>Universidad de Barcelona</u>

Significant Professional Activities Include advisory panels, editorial boards, consulting, honors, awards (reverse chronological order)

Advisory International Panels; IPF-AIR Europa, Roche, Boeringher Int.

Advisory National Panels; Esteve-Teijin, Roche, Boeringher. Int.

Awards; 2003 – Final Specializing Training Award, Hospital Clínic Barcelona, 2008 – Lección Joven SEPAR (national award for young pulmonologists)

Clinical Trials as Principal Investigator:

All of them in IPF;

Fase IV (INPULSIS-ON), Fase III (INPULSIS, CAPACITY), Fase II (RIFF, COMBO, DR127893, PRM-151)

Peer-Reviewed Publications List all, including major reviews and assays (reverse chronological order); Only those papers in press as of June 30, 2016 may be listed. Include all authors, full title, journal, year and full pagination.

- **Molina-Molina M**, Planas-Cerezales L, Perona R. Telomere shortening in idiopathic pulmonary fibrosis. Arch Bronconeumol 2017. Epub ahead of print. **Q2. IF: 2,9**

Applicant (Last, First, Middle): **MARIA MOLINA-MOLINA, MD, PhD**

- Maher TM, **Molina-Molina M**, Russell AM, Bonella F, Jouneau S, Ripamonti E, Axmann J, Vancheri C. Unmet needs in the treatment of idiopathic pulmonary fibrosis-insights from patient chart review in five European countries. *BMC Pulm Med*. 2017;17(1):124.
  - Walsh SLF, Maher TM, Kolb M, Poletti V, Nusser R, Richeldi L, Vancheri C, Wilsher ML, Antoniou KM, Behr J, Bendstrup E, Brown K, Calandriello L, Corte TJ, Cottin V, Crestani B, Flaherty K, Glaspole I, Grutters J, Inoue Y, Kokosi M, Kondoh Y, Kouranos V, Kreuter M, Johannson K, Judge E, Ley B, Margaritopoulos G, Martinez FJ, **Molina-Molina M**, Morais A, Nunes H, Raghu G, Ryerson CJ, Selman M, Spagnolo P, Taniguchi H, Tomassetti S, Valeyre D, Wijsenbeek M, Wuyts W, Hansell D, Wells A; IPF Project Consortium. Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case-cohort study. *Eur Respir J*. 2017;50(2). **Q1. IF: 10.6**
  - Vicens-Zygmunt, S. Estany, A. Colom, A. Montes-Worboys, C. Machahua, AJ Sanabria, R. Llatjós, I. Escobar, F. Manresa, J. Dorca, D. Navajas, J. Alcaraz, **M. Molina-Molina**. Fibroblast viability and phenotypic changes within glycated stiffened three-dimensional collagen matrices. *Respir Res*. 2015;16:82. **Q2. IF: 3.815**
  - **Molina-Molina M**, Xaubet A, Li X, Abdul-Hafez A, Friderici K, Jernigan K, Fu W, Ding Q, Pereda J, Serrano-Mollar A, Casanova A, Rodríguez-Becerra E, Morell F, Ancochea J, Picado C, Uhal BD. Angiotensinogen gene G-6A polymorphism influences idiopathic pulmonary fibrosis disease progression. *Eur Respir J*. 2008;32(4):1004-8. **Q1. IF: 10.6**
  - Estany S, Vicens-Zygmunt V, Llatjós R, Montes A, Penín R, Escobar I, Xaubet A, Santos S, Manresa F, Dorca J, **Molina-Molina M**. Lung fibrotic tenascin-C upregulation is associated with other extracellular matrix proteins and induced by TGFβ1. *BMC Pulm Med*. 2014;14:120. doi: 10.1186/1471-2466-14-120. **Q3. IF: 2.404**
  - Dang MT, Gu C, Klavarian JI, Jernigan KA, Friderici KH, Cui Y, **Molina-Molina M**, Ancochea J, Xaubet A, Uhal BD. Angiotensinogen promoter polymorphisms predict low diffusing capacity in U.S. and Spanish IPF cohorts. *Lung*. 2013;191(4):353-60. **Q2. IF: 2.2**
  - Uhal BD, Dang M, Dang V, Llatjós R, Cano E, Abdul-Hafez A, Markey J, Piasecki CC, **Molina-Molina M**. Cell cycle dependence of ACE-2 explains downregulation in idiopathic pulmonary fibrosis. *Eur Respir J*. 2013;42(1):198-210. doi: 10.1183/09031936.00015612. **Q1. IF: 10.6**
  - Uhal BD, Li X, Piasecki CC, **Molina-Molina M**. Angiotensin signalling in pulmonary fibrosis. *Int J Biochem Cell Biol*. 2012;44(3):465-8. doi: 10.1016/j.biocel.2011.11.019. **Q2. IF: 4.046**
  - Richeldi L, du Bois RM, Raghu G, et al; **INPULSIS Trial Investigators**. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. *N Engl J Med*. 2014; 29:370(22):2071-82. doi: 10.1056/NEJMoa1402584. **D1. IF: 55.87**
  - Robles-Perez A, **Molina-Molina M**. Treatment Considerations of Lung Involvement in Rheumatologic Disease. *Respiration*. 2015;90(4):265-74. doi: 10.1159/000441238. **Q2. IF: 2.593**
  - Robles-Perez A, Luburich P, Rodríguez-Sanchon B, Dorca J, Nolla JM, **Molina-Molina M\***, Narvaez-Garcia J\*. Preclinical lung disease in early rheumatoid arthritis. *Chron Pulm. Med*. 2016;13(1):75-81. **Q2. IF: 2.694**
  - Castillo D, Martín-Arroyo I, Moreno A, Balcells E, Villar A, Vicens-Zygmunt V, Vendrell M7, Belda S, Portillo K, Kettou D, Aparicio F, **Molina-Molina M**. Adult pulmonary Langerhans' cell histiocytosis: approach to the reality of the Spanish population. *Med Clin (Barc)*. 2014 Nov 18;143(10):433-9. **Q2. IF: 1.417**
  - Bonella F, M. Wijsenbeek, **M Molina Molina**, A Duck, W Wuyts. European IPF Patient Charter: unmet needs and a call to action for healthcare policymakers. *Eur Respir J*. 2016; 2016;47(2):597-606. **Q1. IF: 10.6**
  - Gabasa M, Royo D, **Molina-Molina M**, Roca-Ferrer J, Pujols L, Picado C, Xaubet A, Pereda J. Lung myofibroblasts are characterized by down-regulated cyclooxygenase-2 and its main metabolite, prostaglandin E2. *PLoS One*. 2013;8:e65445. **Q1. IF: 3.234**
  - Muñoz-Esquerre M, López-Sánchez M, Escobar I, Huertas D, Penín R, **Molina-Molina M**, Manresa F, Dorca J, Santos S. Systemic and Pulmonary Vascular Remodelling in Chronic Obstructive Pulmonary Disease. *PLoS One*. 2016;11(4):e0152987. **Q1. IF: 3.234**
-

Applicant (Last, First, Middle): **MARIA MOLINA-MOLINA, MD, PhD**

- Gabasa M, Duch P, Jorba I, Giménez A, Lugo R, Pavelescu I, Rodríguez-Pascual F, **Molina-Molina M**, Xaubet A, Pereda J, Alcaraz J. Epithelial contribution to the pro-fibrotic stiff microenvironment and myofibroblast population in lung fibrosis. Mol Biol Cell. 2017. **Q1. IF: 4.02**

-

Active Grants Include only grant title, number, name of principal investigator, name of funding agency, and total award period. Include only active or awarded grants.

- National Registry for Familial Pulmonary Fibrosis.

IP: Maria Molina Molina

Agencia financiadora: ISCIII

Financiación: 150000 euros

Duración: 3 años (2017-2019)

- Efecto de la regulación telomérica en fibrosis pulmonar.

IP: Maria Molina Molina

Agencia financiadora: ISCIII

Financiación: 110715 euros

Duración: 3 años (2016-2018)

Expediente: PI15/00710

- Efecto de la glicación y el envejecimiento celular en la fibrogénesis pulmonar: posibles vías para su regulación.

IP: Maria Molina Molina

Agencia financiadora: ISCIII

Financiación: 143000 euros

Duración: 3 años (2013-2015)

Expediente: PI12/02455

Principal investigator in 9 clinical trials in ILD (IPF, FPF, Alveolar Proteinosis, LAM, Progressive PF, Unclassifiable progressive pulmonary fibrosis).

Investigator in international multicentre networks for ILDs: EuIPF Registry, DNA consortium, ILD REG Group.

---